Development of a combined In-Cell ELISA and flow cytometry method for quantification of uptake of PEGylated nanoparticles by Raw264.7 and HepG2 cells
Cancer is one of today’s most common causes of human mortality. For long, chemotherapeutics has been a conventional treatment of the disease, but due to its low precision and high frequency of side effects, this treatment has been highly debated. Nanosized particles, so called nanoparticles (NPs), have emerged as a promising tool for cancer treatment, due to their ability of selectively reaching t